Research Interests
Open to PhD applications in the field of
- Cancer pharmacology
- Breast and Ovarian cancer
- Mechanism of drug action
- Chemoresistance
- Stratification biomarker development
- Cell and molecular biology
Current Research Opportunities
- To investigate novel interacting drug combinations in the treatment of Ovarian Cancer
- Dissecting mechanism of drug responses to novel anti-cancer therapies
Public outreach & key achievements
Research students
| PhD Title | Overexpression and regulation of HDAC6 in the pathogenesis of Breast Cancer |
| Name | Asaad Leen |
| Country | Jordan |
| Year of Study | 1st |
| PhD Title | Dissecting the mode of action of DREAM inhibition in breast cancer |
| Name | Alhussein Ali S Khawaji |
| Country | Saudi Arabia |
| Year of Study | 1st |
| PhD Title | Dissecting the Mode of Action of HDAC6 Inhibition in Cancer |
| Name | Yangyang Wang |
| Country | China |
| Year of Study | 3rd |
| PhD Title | Investigation of Chemically Modified MicroRNA in Chemoresistant Breast Cancer |
| Name | Fengyu Zhang |
| Country | China |
| Year of Study | 3rd |
Alumni: Where are they now
| PhD Title | The contribution of the microRNA miR-433 to the pathology of ovarian cancer |
| Name | Dr Karolina Weiner-Gorzel |
| Year of Study | 2010 - 2014 |
| Country | Ireland |
| Current Position | 3rd year Graduate entry medicine Student at University College Cork, Ireland. |
| PhD Title | The evaluation of the effects of the mitotic arrest deficiency protein 2 (MAD2) and the miR-433 microRNA on chemoresistance and cancer prognosis. |
| Name | Dr Tara Byrne |
| Year of Study | 2013 - 2017 |
| Country | Northern Ireland |
| Current Position | Team Leader, Randox |